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Veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) support for postcardiotomy 
cardiogenic shock (PCS) in patients undergoing surgery for acute type A aortic dissection (TAAD) is 
controversial and the available evidence is confined to limited case series. We aimed to evaluate the 
impact of this salvage therapy in this patient population. Between January 2010 and March 2018, all 
TAAD patients receiving VA-ECMO for PCS were retrieved from the PC-ECMO registry. Hospital 
mortality and other secondary outcomes were compared with PCS patients undergoing surgery for 
other cardiac pathologies and treated with VA-ECMO. Among the 781 patients in the PC-ECMO 
registry, 62 (7.9%) underwent TAAD repair and required VA-ECMO support for PCS. In-hospital 
mortality accounted for 46 (74.2%) patients, while 23 (37.1%) were successfully weaned from VA-
ECMO. No significant differences were observed between the TAAD and non-TAAD cohorts with 
reference to in-hospital mortality (74.2 vs 63.4%, p = 0.089). However, patients in the TAAD group 
had a higher rate of neurological events (33.9 vs 17.6%, p = 0.002), but similar rates of reoperation for 
bleeding/tamponade (48.4 vs 41.5%, p = 0.29), transfusion of ≥10 red blood cell units (77.4 vs 69.5%, 
p = 0.19), new-onset dialysis (56.7 vs 53.1%, p = 0.56), and other secondary outcomes.  
VA-ECMO provides a valid support for patients affected by PCS after surgery for TAAD. 
 
 
Trial Registration: Clinicaltrials.gov - NCT03508505 
 
 
Keywords: Extracorporeal membrane oxygenation; ECMO, ECLS; Postcardiotomy; Cardiac surgery; 
Heart failure; Aortic dissection. 
 
 






Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) provides temporary mechanical 
circulatory support for patients affected by postcardiotomy cardiogenic shock (PCS), allowing for 
cardiopulmonary recovery.
1,2
 However, complications and mortality rates after postcardiotomy VA-
ECMO remain high, with reported successful weaning from VA-ECMO and hospital mortality 
between 40% to 70%, and 50 to 80%, respectively.
2-6
 Therefore, selection of patients requiring VA-
ECMO is a crucial element for a successful postoperative outcome. In this context, the efficacy of VA-
ECMO in patients undergoing surgery for acute type A aortic dissection (TAAD) is controversial, and 
available data is confined to limited case series.
7-10
 We report the outcome of patients with PCS 
following TAAD repair from the multicentre Postcardiotomy Veno-arterial Extracorporeal Membrane 
Oxygenation (PC-ECMO) registry. 
 
Methods 
 The patient population was collected from the observational, multicenter PC-ECMO registry 
that enrolled patients undergoing VA-ECMO following adult cardiac surgery at 19 centers from 
Belgium, Czech Republic, Finland, France, Germany, Italy, Saudi Araba, Sweden, and the United 
Kingdom from January 2010 to March 2018. The present study is registered at 
http://www.clinicaltrials.gov (unique identifier: NCT03508505) and was approved by local or regional 
Institutional Review Boards, where applicable. The detailed protocol with definition criteria has been 
published previously.
6
 The study complies with the Strengthening the Reporting of Observational 




 Only patients affected by PCS following TAAD repair requiring VA-ECMO support were 
included in this analysis. Baseline characteristics, demographics, comorbidities, intraoperative factors, 
postoperative outcomes, and VA-ECMO related data were recorded, and variable definitions have 
been previously reported.
6
 The main outcome measure was in-hospital mortality, while secondary 
outcomes included death on VA-ECMO, reoperation for bleeding/tamponade, postoperative 
neurological and renal complications, sternal wound infection, red blood cell transfusion, and the 
length of stay in hospital and the intensive care unit.   





 Statistical analyses were performed using the SPSS statistical software v. 24.0 (IBM 
Corporation, Armonk, NY, USA), and Stata v. 15.1 (SAS Institute Inc., Cary, NC, USA). Covariates 
and outcomes were reported as counts and percentages, and as mean and standard deviation or median 
and interquartile range (IQR). The Mann-Whitney U, chi-square, and Fisher’s exact tests were used 
for univariate analysis. The impact of aortic dissection on hospital mortality was adjusted for the PC-
ECMO score
6
 in the logistic regression analysis. A p<0.05 was set for statistical significance. 
 
Results 
 Among the 781 patients of the PC-ECMO registry, 62 (7.9%) underwent TAAD repair and 
required VA-ECMO support for PCS. Mean age was 62.9 ± 11.0 years (range: 33-79 years) and 17 
(27.4%) were female patients. When compared with patients without TAAD diagnosis, those affected 
by TAAD did not differ in their demographics or comorbidity profile (Table 1). The two groups 
exhibited significant differences in reference to cardiac presentation, duration and type of operation, 
which significantly increased their risk profile (Tables 1 and 2). Moreover, patients undergoing TAAD 
repair had higher lactate levels before VA-ECMO institution (8.6 ± 4.8 mmol/L vs 6.8 ± 4.7 mmol/L, 
p=0.002), and ECMO support was more often started immediately after surgery (74.2% vs 59.5%, 
p=0.023). Outcomes are summarized in Table 3.  
 Twenty-three (37.1%) patients were successfully weaned from VA-ECMO, and in-hospital 
mortality accounted for 46 (74.2%) patients, with no statistical difference when VA-ECMO was 
instituted immediately after surgery or later (76.1% versus 68.8%, P=0.74). Also, no differences were 
observed between the TAAD and non-TAAD cohorts in reference to in-hospital mortality (74.2% vs 
63.4%, p=0.089). Patients in the TAAD group had a higher rate of neurological events (33.9% vs 
17.6%, p=0.002), but similar rates of reoperation for bleeding/tamponade (p=0.29), RBC transfusion 
(p=0.19), renal failure (p=0.56), and other analysed secondary outcomes. In-hospital mortality did not 
differ even when adjusted for preoperative neurological events (OR 0.39, 95%CI 0.82-2.71) and for 
the PC-ECMO score (OR 0.892, 95%CI 0.46-1.73). Conversely, the TAAD cohort experienced a 
lower hospital and intensive care unit stay (11.9 ± 16.9 days vs 17.6 ± 18.3 days, p<0.0001, and 16.6 ± 
27.8 days vs 25.8 ± 31.7 days, p<0.0001) (Table 3). However, when patients who survived were 





considered alone, , no differences in hospital and intensive care unit stay were observed (28.1 ± 23.6 
vs 27.9 ± 21.5 days, p=0.74, and 45.1 ± 41.3 vs 47.5 ± 39.1 days, p=0.32, respectively).  
 
Discussion 
 The present study is the largest analysis on the impact of VA-ECMO on the survival of 
patients with PCS after TAAD repair. In this cohort of patients, VA-ECMO proved to be a valid 
rescue option with similar hospital mortality and postoperative outcomes to other PCS patients who 
underwent surgery for other cardiac pathologies. This finding is of relevance since the use of intra-
aortic balloon pump is contraindicated in those who underwent TAAD repair who develop PCS due to 
the coexistence of descending thoracic and abdominal aorta dissection.
7,12,13
 Therefore, in this cohort 
of patients, VA-ECMO is the only temporary circulatory support strategy available.  
 Despite the fact that VA-ECMO is a well-established hemodynamic rescue option for 
cardiogenic shock, acute myocarditis, PCS or periprocedural support in acute decompensated heart 
failure, its role in postoperative TAAD setting remains controversial, and the available evidence from 
literature remains undoubtedly limited.
7-10
 The evaluation of the outcome of PCS in this patient 
population is of significant value as TAAD patients have an inherently high operative risk, and 
surgical repair for TAAD is rather complex and involve a prolonged period of myocardial ischemia, 
cardiopulmonary bypass and the use of hypothermic circulatory arrest. In addition, TAAD surgical 
repair is often complicated by severe end-organ injury other than heart failure. Furthermore, fragile 
tissues and prolonged surgery may result in excessive bleeding, which may further aggravate the 
recovery of patients affected by TAAD. Sultan et al.
8 
retrospectively reviewed TAAD patients 
undergoing surgical repair and VA-ECMO implantation over a 10-year period. Thirty-five TAAD 
cases were identified, and the observed in-hospital mortality was 88.6%, leading to questioning the use 
of VA-ECMO in this cohort of patients.
8
 
 Conversely, Lin et al.
9
 demonstrated that VA-ECMO was a reasonable treatment for TAAD 
patients with refractory postcardiotomy cardiac failure. They compared TAAD patients requiring 
postoperative VA-ECMO support to those who did not, and 20 (12.3%) patients among a total of 162 
required ECMO support. Although observed mortality was significantly higher in the cohort requiring 
VA-ECMO support (65% vs. 8.5%), long-term survival was comparable between the study groups.
9
 





Finally, Wang et al.
10
 analysed 246 consecutive TAAD patients with seven patients supported 
postoperatively by VA-ECMO for refractory cardiogenic shock. Among those, only one patient died, 
leading the authors to conclude that ECMO provides good temporary cardiopulmonary support even in 
this high-risk patient population. Our data corroborate this evidence. TAAD patients who developed 
PCS and were treated with VA-ECMO had significant operative mortality, which was comparable to 
that of the second cohort of patients who underwent surgery for other cardiac pathologies and required 
postcardiotomy VA-ECMO. This proves that the occurrence of PCS rather than the type of surgery has 
an impact on the outcome.
1,2
 In fact, a recent large multicenter study on VA-ECMO that included more 
than 8000 patients affected by cardiogenic shock, showed a remarkable increase of more than 30-fold 
in the use of VA-ECMO, but with unaltered in-hospital mortality.
2
 Similarly, in the PC-ECMO 
registry, the year of operation did not have any impact on perioperative outcomes, with an equivalent 
in-hospital mortality over a 9-year period.
5
 
 Between the two patient cohorts, no differences were observed in reference to postoperative 
reoperation for bleeding/tamponade and blood transfusion rates. Although TAAD patients are 
intrinsically associated with longer cardiopulmonary bypass times and higher blood product 
transfusion demands, VA-ECMO support did not increase the risk of postoperative bleeding or the 
related sequelae of multiorgan failure and infections in comparison with other PCS patients 
undergoing cardiac surgery for other pathologies.
14,15
 As expected, neurological events differed 
between the two groups, where patients in the TAAD group were more often subjected to preoperative 




 Another interesting finding of the present study is the shorter intensive care unit stay and 
hospitalization in the TAAD cohort. A plausible explanation is related to the critical status of these 
patients at presentation, including life-threatening conditions, for instance, organ malperfusion, acute 
myocardial infarction and cerebrovascular accidents.
14
 This can overcome the benefit of the short-term 
 VA-ECMO support. As a matter of fact, the TAAD cohort required a more immediate VA-
ECMO implantation and a shorter duration of the mechanical support. Another possible explanation is 
the fact that some of TAAD patients presenting with acute cardiac failure and myocardial stunning and 
promptly supported by VA-ECMO, rapidly return to almost a normal cardiac function after surgery.
9
 It 





is not a surprise that after this critical early postoperative period, survival rates are similar between 
TAAD patients supported by VA-ECMO and other non-ECMO surgical patients.
9 
 Our study has several limitations. Firstly, inherent bias to the observational nature of the 
present series cannot be excluded. The PC-ECMO registry includes a consecutive series of patients 
treated in university hospitals and regional tertiary hospitals in different European countries, possibly 
leading to the enrolment of a more inclusive patient population undergoing TAAD repair in centers 
with different referral pathways, preoperative selection criteria, and treatment strategies which makes 
the present results generalizable in different healthcare systems. Secondly, because the observational 
nature of this registry, which included only patients who underwent postcardiotomy VA-ECMO, we 
were not able to compare the outcome of patients with TAAD requiring VA-ECMO with those not 
requiring VA-ECMO support. Lastly, the sample size of our series remains small for an adequate and 
detailed sub-group analyses. Despite these limitations, our cohort is currently the largest available 
series and provides new data on the potential benefits of using VA-ECMO in TAAD patients affected 
by postoperative PCS. 
 In conclusion, our study demonstrated that VA-ECMO is a valid treatment strategy for 
patients undergoing surgery for acute type A aortic dissection and affected by postcardiotomy 
cardiogenic shock. Mortality and other secondary outcomes, including the risk of postoperative 
bleeding, are similar to other PCS patients undergoing surgery for other cardiac pathologies. 
Therefore, the concept whereby TAAD patients undergoing surgical repair and affected by PCS are at 
prohibitive risk for VA-ECMO should be challenged.   
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Table 1  







 p value 
   Age (years) 62.9 ± 11.0 63.1 ± 13.1 0.58 
   Women 17 (27.4%) 232 (32.3%) 0.43 
   Body mass index (kg/m
2
)  26.8 ± 5.0 27.2 ± 5.1 0.66 
Presentation and cardiac status 
   Urgent/emergent  55 (88.7%) 398 (55.4%) <0.0001 
   Critical preoperative state 25 (40.3%) 251 (34.9%) 0.39 
   Preoperative stroke/unconsciousness 8 (12.9%) 19 (2.6%) <0.0001 
   Prior cardiac surgery 14 (22.6%) 172 (23.9%) 0.81 
   Prior myocardial infarction 8 (12.9%) 191 (26.6%) 0.018 
Comorbidities 
   Diabetes mellitus 7 (11.3%) 193 (26.8%) 0.007 
   Haemoglobin (g/L) 123.1 ± 23.9 125.4 ± 21.8 0.89 
   Estimated glomerular filtration rate  (mL/min/1.73 m
2
) 66.3 ± 24.9 68.1 ± 30.7 0.79 
   Dialysis 3 (4.8%) 29 (4.0%) 0.74 
   Stroke 5 (8.1%) 55 (7.6%) 0. 91 
   Extracardiac arteriopathy 8 (12.9%) 110 (15.3%) 0.61 
   Pulmonary disease 10 (16.1%) 100 (13.1%) 0.63 
   Atrial fibrillation 13 (21.0%) 179 (24.9%) 0.49 
   PC-ECMO†, score 6.1 ± 3.2 3.7 ± 2.3 <0.0001 
   EuroSCORE 2, score (%) 15.3 ± 17.3 18.9 ± 15.6 0.003 
 
TAAD, type A aortic dissection.     
   *Continuous data are presented as mean ± standard deviation; categorical variables as number (percent). 
     †
PC-ECMO score is based on the following rik factors: age (60-69 tears, ≥70 years – points 2 or 4, 
respectively), female gender (points 1), prior cardiac surgery (points 1), arterial lactate ≥6 mmol/L (points 2), 






















Table 2  








ACC time (minutes)  181± 238  122 ± 78 0.001 
Median 139.5 (85) 106 (94)  
CPB time (minutes)  295 ± 117 218 ± 121 <0.0001 
Median 218 (160) 277 (117)  
Surgical procedures 
   Aortic procedures  62 (100%) 93 (12.9%) <0.0001 
      Aortic root surgery 20 (32.3%) 67 (9.3%) <0.0001 
      Isolated ascending aorta repair 33 (53.2%) 21 (2.9%) <0.0001 
      Aortic arch repair 26 (41.9%) 13 (1.8%) <0.0001 
   Aortic valve replacement/repair   9 (14.5%) 211 (29.3%) 0.008 
 Mitral valve surgery 2 (3.2%) 266 (37.0%) <0.0001 
 Tricuspid valve surgery - 100 (13.9%) <0.0001 
 Coronary surgery 16 (25.8%) 374 (52.0%) <0.0001 
 Other procedures 1 (1.6%) 74 (10.3%) 0.026 
Timing of ECMO insertion 
   VA-ECMO inserted immediately after surgery 46 (74.2%) 428 (59.5%) 0.023 
   Duration of ECMO support, days 5.1 ± 5.2 7.1 ± 6.3 0.003 
Median 3.0 (7.0) 6.0 (7.0)  
   Central arterial cannulation 19 (30.6%) 226 (31.4%) 0.99 
   Arterial lactate before VA-ECMO, mmol/L 6.8 ± 4.7 8.6 ± 4.8 0.002 
Median 7.2 (4.8) 5.6 (6.3)  
 
    ACC, aortic cross clamp; CPB, cardiopulmonary bypass; VA-ECMO, veno-arterial extracorporeal membrane 
oxygenation.  
    *Continuous data are presented as mean (standard deviation) and median (interquartile range); categorical 






























   In-hospital mortality 46 (74.2%) 456 (63.4%) 0.089 
Secondary end-points 
   In-hospital mortality on VA-ECMO 41 (66.1%) 329 (45.8%) 0.002 
   Reoperation for bleeding/tamponade 30 (48.4%) 298 (41.5%) 0.29 
   Stroke/Global brain ischemia 21 (33.9%) 126 (17.6%) 0.002 
   Dialysis (new-onset) 34 (56.7%) 375 (53.1%) 0.59 
   Liver failure 19 (30.6%) 246 (34.3%) 0.56 
   Deep sternal wound infection 1 (1.6%) 28 (3.9%) 0.72 
   Blood stream infection 12 (19.4%) 167 (23.2%) 0.47 
   RBC > 9 units 48 (77.4%) 499 (69.5%) 0.19 
   RBC units transfused (units) 29.9 ± 21.0 23.1 ± 22.0 0.060 
Median 20.0 (30) 15.0 (23)  
   Pneumonia 17 (27.4%) 268 (37.3%) 0.12 
Length of stay 
  Intensive care unit stay (days) 11.9 ± 16.9 17.6 ± 18.3 <0.0001 
Median 6.0 (14.0) 12 (19)  
  Hospital stay (days) 16.6 ± 27.8  25.8 ± 31.7 <0.0001 
Median 6.5 (15.0) 17.0 (27.0)  
    VA-ECMO, veno-arterial extracorporeal membrane oxygenation.  
    *Continuous data are presented as mean (standard deviation) or median [interquartile range]; 





         
